Transenterix Inc (NASDAQ:TRXC) has been assigned an average broker rating score of 1.20 (Strong Buy) from the five brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and four have issued a strong buy recommendation on the company.
Brokerages have set a one year consensus price objective of $6.70 for the company and are anticipating that the company will post ($0.12) EPS for the current quarter, according to Zacks. Zacks has also assigned Transenterix an industry rank of 101 out of 265 based on the ratings given to its competitors.
Transenterix (NASDAQ:TRXC) opened at 2.48 on Monday. The company’s market capitalization is $248.35 million. The stock’s 50 day moving average price is $2.49 and its 200-day moving average price is $2.69. Transenterix has a 52-week low of $2.07 and a 52-week high of $4.87.
Several research analysts recently weighed in on TRXC shares. BTIG Research reiterated a “buy” rating and set a $6.00 price target on shares of Transenterix in a research report on Wednesday, October 7th. Zacks Investment Research upgraded Transenterix from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Friday, September 25th. Finally, RBC Capital restated an “outperform” rating and issued a $6.00 price objective on shares of Transenterix in a research report on Monday, September 28th.
In other Transenterix news, Director Andrea Biffi acquired 25,000 shares of the stock in a transaction dated Monday, November 16th. The stock was acquired at an average price of $2.81 per share, with a total value of $70,250.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at $140,500. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Willam N. Kelley acquired 20,000 shares of the stock in a transaction dated Friday, November 13th. The stock was acquired at an average cost of $2.80 per share, with a total value of $56,000.00. The disclosure for this purchase can be found here.
TransEnterix, Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (NASDAQ:TRXC). The Company’s SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System, (the SPIDER System) a manual laparoscopic system in the United States, Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon, allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com